3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Advanced Malignancies
1
Advanced Cancer
1
Interventions
Paclitaxel
68
Carboplatin
64
pembrolizumab
32
Cyclophosphamide
32
Bevacizumab
27
liposomal doxorubicin
24
Cisplatin
24
Topotecan
21
Gemcitabine
21
olaparib
18
fludarabine
17
Taxes
16
Docetaxel
15
Nivolumab
14
Doxorubicin
14
niraparib
13
veliparib
12
Albumin-Bound Paclitaxel
11
aldesleukin
9
Filgrastim
9
fludarabine phosphate
8
durvalumab
8
Oxaliplatin
8
Fluorouracil
8
Drug Therapy
8
sargramostim
7
Peripheral Blood Stem Cell Transplantation
7
Magnetic Resonance Spectroscopy
7
Leucovorin
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Ovarian Neoplasms
×
cabiralizumab
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts